Inhibition of Cdk5 increases osteoblast differentiation and bone mass and improves fracture healing
Open Access
- 6 April 2022
- journal article
- research article
- Published by Springer Nature in Bone Research
- Vol. 10 (1) , 1-13
Abstract
Identification of regulators of osteoblastogenesis that can be pharmacologically targeted is a major goal in combating osteoporosis, a common disease of the elderly population. Here, unbiased kinome RNAi screening in primary murine osteoblasts identified cyclin-dependent kinase 5 (Cdk5) as a suppressor of osteoblast differentiation in both murine and human preosteoblastic cells. Cdk5 knockdown by siRNA, genetic deletion using the Cre-loxP system, or inhibition with the small molecule roscovitine enhanced osteoblastogenesis in vitro. Roscovitine treatment significantly enhanced bone mass by increasing osteoblastogenesis and improved fracture healing in mice. Mechanistically, downregulation of Cdk5 expression increased Erk phosphorylation, resulting in enhanced osteoblast-specific gene expression. Notably, simultaneous Cdk5 and Erk depletion abrogated the osteoblastogenesis conferred by Cdk5 depletion alone, suggesting that Cdk5 regulates osteoblast differentiation through MAPK pathway modulation. We conclude that Cdk5 is a potential therapeutic target to treat osteoporosis and improve fracture healing.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (CRC1149 (INST 40/492-2), CRC1149 (INST 40/492-1))
This publication has 74 references indexed in Scilit:
- Inhibition of GSK-3β Rescues the Impairments in Bone Formation and Mechanical Properties Associated with Fracture Healing in Osteoblast Selective Connexin 43 Deficient MicePLOS ONE, 2013
- Interplay between MEK-ERK signaling, cyclin D1, and cyclin-dependent kinase 5 regulates cell cycle reentry and apoptosis of neuronsMolecular Biology of the Cell, 2012
- Disorders of Bone RemodelingAnnual Review of Pathology: Mechanisms of Disease, 2011
- A High-Resolution Anatomical Atlas of the Transcriptome in the Mouse EmbryoPLOS Biology, 2011
- Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignanciesEuropean Journal of Cancer, 2010
- Extracellular Signal-Regulated Kinase 1 (ERK1) and ERK2 Play Essential Roles in Osteoblast Differentiation and in Supporting OsteoclastogenesisMolecular and Cellular Biology, 2009
- Pharmacologic Inhibition of the TGF-β Type I Receptor Kinase Has Anabolic and Anti-Catabolic Effects on BonePLOS ONE, 2009
- Micro-computed tomography assessment of fracture healing: Relationships among callus structure, composition, and mechanical functionBone, 2009
- A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 daysBritish Journal of Cancer, 2006
- Molecular model of cyclin-dependent kinase 5 complexed with roscovitineBiochemical and Biophysical Research Communications, 2002